These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 20525842

  • 1. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial.
    Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, Campos L, Häfner R, Hofer M, Ozen S, Huemer C, Bae SC, Sztajnbok F, Arguedas O, Foeldvari I, Huppertz HI, Gamir ML, Magnusson B, Dressler F, Uziel Y, van Rossum MA, Hollingworth P, Cawkwell G, Martini A, Ruperto N, Pediatric Rheumatology International Trials Organisation (PRINTO).
    Ann Rheum Dis; 2010 Aug; 69(8):1479-83. PubMed ID: 20525842
    [Abstract] [Full Text] [Related]

  • 2. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.
    Céspedes-Cruz A, Gutiérrez-Suárez R, Pistorio A, Ravelli A, Loy A, Murray KJ, Gerloni V, Wulffraat N, Oliveira S, Walsh J, Penades IC, Alpigiani MG, Lahdenne P, Saad-Magalhães C, Cortis E, Lepore L, Kimura Y, Wouters C, Martini A, Ruperto N, Pediatric Rheumatology International Trials Organization (PRINTO).
    Ann Rheum Dis; 2008 Mar; 67(3):309-14. PubMed ID: 17875547
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
    Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A, Pediatric Rheumatology International Trials Organization.
    Arthritis Rheum; 2004 Jul; 50(7):2191-201. PubMed ID: 15248217
    [Abstract] [Full Text] [Related]

  • 4. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis.
    Bartoli M, Tarò M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, Magnani A, Gasparini C, Martini A, Ravelli A.
    Ann Rheum Dis; 2008 Mar; 67(3):370-4. PubMed ID: 17660217
    [Abstract] [Full Text] [Related]

  • 5. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 6. [Methotrexate treatment in refractory juvenile rheumatoid arthritis].
    Brik R.
    Harefuah; 1998 Dec 01; 135(11):509-11, 567. PubMed ID: 10911466
    [Abstract] [Full Text] [Related]

  • 7. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
    Ringold S, Chon Y, Singer NG.
    Arthritis Rheum; 2009 Dec 01; 60(12):3776-83. PubMed ID: 19950286
    [Abstract] [Full Text] [Related]

  • 8. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
    Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2011 Sep 01; 70(9):1605-12. PubMed ID: 21623000
    [Abstract] [Full Text] [Related]

  • 9. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.
    Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le Cessie S, Huizinga TW, Ten Cate R, Guchelaar HJ.
    Arthritis Rheum; 2009 Jan 15; 61(1):46-51. PubMed ID: 19116975
    [Abstract] [Full Text] [Related]

  • 10. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis.
    Papadopoulou C, Kostik M, Böhm M, Nieto-Gonzalez JC, Gonzalez-Fernandez MI, Pistorio A, Martini A, Ravelli A.
    J Pediatr; 2013 Sep 15; 163(3):879-84. PubMed ID: 23664559
    [Abstract] [Full Text] [Related]

  • 11. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M, Zwicker M, Villiger PM.
    J Rheumatol; 2003 Jan 15; 30(1):28-35. PubMed ID: 12508386
    [Abstract] [Full Text] [Related]

  • 12. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan 15; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 13. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, Duffy C, Howard P, Strand V.
    Arthritis Rheum; 2005 Feb 15; 52(2):554-62. PubMed ID: 15693001
    [Abstract] [Full Text] [Related]

  • 14. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome.
    Ruperto N, Ravelli A, Levinson JE, Shear ES, Murray K, Link Tague B, Martini A, Glass DN, Giannini EH.
    J Rheumatol; 1997 May 15; 24(5):952-8. PubMed ID: 9150088
    [Abstract] [Full Text] [Related]

  • 15. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
    Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2007 Sep 15; 56(9):3096-106. PubMed ID: 17763439
    [Abstract] [Full Text] [Related]

  • 16. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec 15; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F.
    Arthritis Rheum; 2005 Feb 15; 52(2):548-53. PubMed ID: 15693004
    [Abstract] [Full Text] [Related]

  • 18. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease.
    Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E, Viola S, Martini A.
    Arthritis Rheum; 2005 Mar 15; 52(3):826-32. PubMed ID: 15751057
    [Abstract] [Full Text] [Related]

  • 19. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
    Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I.
    Arthritis Rheum; 2000 Aug 15; 43(8):1849-57. PubMed ID: 10943876
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
    van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, ten Cate R, van Suijlekom-Smit LW, Wulffraat NM, van Luijk WH, Oostveen JC, Kuis W, Dijkmans BA, Dutch Juvenile Idiopathic Arthritis Study group.
    Ann Rheum Dis; 2007 Nov 15; 66(11):1518-24. PubMed ID: 17491099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.